The head of pharmaceutical drug purchasing for Oregons Medicaid program has a message to hepatitis C drug makers Lets make a deal Oregon is seeking to severely restrict use of Sovaldi  the  hepatitis C pill sold by Gilead Sciences  among Medicaid beneficiaries and expects competing treatments to come on the US market in the next year And when one or more of those new treatments does become available Oregon will start bargaining for a deep discount  perhaps as much as   in exchange for reimbursing the winning drug makers therapy for Oregon beneficiaries Thomas Burns pharmacy director for the Oregon Health Authority tells us